Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Granulocyte colony-stimulating factors: finding the right indication.

Publication ,  Journal Article
Lyman, GH; Shayne, M
Published in: Curr Opin Oncol
July 2007

PURPOSE OF REVIEW: Neutropenic complications including febrile neutropenia represent major dose-limiting toxicities of cancer chemotherapy. Recommendations for the use of recombinant myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity continue to evolve. RECENT FINDINGS: Several randomized controlled trials and meta-analyses have confirmed that the myeloid growth factors reduce the risk of neutropenic complications and may facilitate delivered dose intensity in patients receiving cancer chemotherapy. Older age and certain comorbidities significantly increase the risk of febrile neutropenia and its consequences. Three new clinical practice guidelines for the use of the myeloid growth factors have been published by major professional oncology organizations including the American Society of Clinical Oncology, the European Organization for Research and Treatment of Cancer and the National Comprehensive Cancer Network. The recommendations and evidence basis for these guidelines are presented here. All three new or updated guidelines recommend prophylactic use of the myeloid growth factors in cancer patients receiving chemotherapy at 20% or greater risk of febrile neutropenia and in those with important variables that increase individual risk of neutropenic complications. SUMMARY: Consistent clinical practice guidelines based on multiple randomized control trials and meta-analyses should further guide the appropriate and cost-effective use of these agents.

Duke Scholars

Published In

Curr Opin Oncol

DOI

ISSN

1040-8746

Publication Date

July 2007

Volume

19

Issue

4

Start / End Page

299 / 307

Location

United States

Related Subject Headings

  • Risk Factors
  • Recombinant Proteins
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Intercellular Signaling Peptides and Proteins
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Evidence-Based Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Shayne, M. (2007). Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol, 19(4), 299–307. https://doi.org/10.1097/CCO.0b013e3281a3c0ba
Lyman, Gary H., and Michelle Shayne. “Granulocyte colony-stimulating factors: finding the right indication.Curr Opin Oncol 19, no. 4 (July 2007): 299–307. https://doi.org/10.1097/CCO.0b013e3281a3c0ba.
Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007 Jul;19(4):299–307.
Lyman, Gary H., and Michelle Shayne. “Granulocyte colony-stimulating factors: finding the right indication.Curr Opin Oncol, vol. 19, no. 4, July 2007, pp. 299–307. Pubmed, doi:10.1097/CCO.0b013e3281a3c0ba.
Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007 Jul;19(4):299–307.

Published In

Curr Opin Oncol

DOI

ISSN

1040-8746

Publication Date

July 2007

Volume

19

Issue

4

Start / End Page

299 / 307

Location

United States

Related Subject Headings

  • Risk Factors
  • Recombinant Proteins
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Intercellular Signaling Peptides and Proteins
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Evidence-Based Medicine